证券代码：301293 证券简称：三博脑科 公告编号：2026-009 三博脑科医院管理集团股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2026 年 3 月 5 日召开第三届董事会第十七次会议，审议通过了《关于使用闲置募集资金进行 现金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行和募集资 金安全的情况下，使用额度不超过 6,000 万元（含本数）闲置募集资金进行现金 管理，该额度自董事会审议通过之日起 12 个月内均可使用。在上述额度和期限 内，资金可滚动使用，单个现金管理产品的投资期限不超过 12 个月。现将具体 情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可〔2023〕 534 号文《关于同意三博脑科医院管理集团股份有限公司首次公开发行股票注册 的批复》同意注册，并经深圳证券交易所同意，公司首次公开发行人民币普通股 （A 股）39,612,900 股，每股面值人民币 1.00 元， ...

三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2026 年 3 月 5 日召开第三届董事会第十七次会议，审议通过了《关于变更募集资金专户的议 案》。公司此次变更募集资金专用账户，未改变募集资金用途，不影响募集资金 投资计划。现将有关事宜公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可〔2023〕534 号文《关于同意三博脑科医院管理集团股份有限公司首次公开发行股票注册的批 复》同意注册，并经深圳证券交易所同意，公司首次公开发行人民币普通股（A 股）39,612,900 股，每股面值人民币 1.00 元，发行价格为 29.60 元/股。本次发行 募集资金总额 117,254.1840 万元；扣除发行费用（不含增值税）后，募集资金净 额为 106,163.91 万元，募集资金已于 2023 年 4 月 27 日划至公司指定账户，立信 会计师事务所（特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了 审验，并于 2023 年 4 月 27 日出具了"信会师报字[2023]第 ZB10925 号"《验资报 告》。公司已对募集资金采取了专户存储，并与专户银行、 ...

证券代码：301293 证券简称：三博脑科 公告编号：2026-008 三博脑科医院管理集团股份有限公司 关于变更注册地址并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2026 年 3 月 5 日召开第三届董事会第十七次会议，审议通过了《关于变更注册地址并修订<公 司章程>的议案》。 一、《公司章程》修订情况 因经营发展需要，公司已搬迁至新办公地址，公司拟将注册地址由"北京市 海淀区香山一棵松 50 号 23 号楼 105 室"变更为"北京市海淀区板井路 69 号世 纪金源商务中心写字楼 3 层 A"。 基于以上注册地址的变更，公司将同步修订《公司章程》相关条款，具体如 下： | 修订前 | | | 修订后 | | --- | --- | --- | --- | | 第五条 | | 公司住所：北京市海淀区香山 | 第五条 公司住所：北京市海淀区板井 | | 一棵松 50 23 | 号 | 号楼 105 室 | 路69号世纪金源商务中心写字楼3层A | | 邮政编码：100093 ...

证券代码：301293 证券简称：三博脑科 公告编号：2026-011 三博脑科医院管理集团股份有限公司 关于召开 2026 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 03 月 24 日 15:30:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 03 月 24 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2026 年 03 月 24 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登 ...

证券代码：301293 证券简称：三博脑科 公告编号：2026-007 三博脑科医院管理集团股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三博脑科医院管理集团股份有限公司（以下简称"公司"）第三届董事会第十 七次会议于 2026 年 3 月 5 日在公司会议室以现场结合通讯的方式召开。会议通 知于 2026 年 3 月 2 日以电子邮件等方式发出。本次会议应出席董事 9 名，实际 出席的董事 9 人，会议由董事长张阳先生主持，公司高级管理人员列席了会议。 本次会议的召集、召开和表决程序符合《公司法》等法律法规和《公司章程》的 有关规定。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于变更注册地址并修订<公司章程>的议案》 因经营发展需要，公司已搬迁至新办公地址，公司拟将注册地址由"北京市 海淀区香山一棵松 50 号 23 号楼 105 室"变更为"北京市海淀区板井路 69 号世 纪金源商务中心写字楼 3 层 A"。 基于以上注册地址的变更，公司将同 ...

Group 1: Stock Price Fluctuation Reasons - The stock price movement of Sanbo Brain Science (301293) is primarily influenced by the hype surrounding brain-computer interface concepts, the company's fundamental situation, and significant event developments [1] - Since the beginning of 2026, brain-computer interfaces have become a market hotspot, driven by Neuralink's announcement of starting device mass production in 2026 and domestic policies promoting brain-computer interfaces as a future industry [2] - Sanbo Brain Science's stock price surged nearly 60% from January 5 to January 8, but later corrected after the company clarified that its brain-computer interface business is still in the experimental stage and will not significantly impact current performance [2] Group 2: Company Fundamentals - For the third quarter of 2025, Sanbo Brain Science reported total revenue of 1.273 billion yuan, a year-on-year increase of 20.26%, but the net profit attributable to shareholders decreased by 20.01% to 83.6282 million yuan [3] - The profit decline is mainly due to new hospital expansions in Kunming and Xi'an, which are in the investment phase, leading to significant increases in depreciation, amortization, and labor costs, while revenue has not fully materialized [3] - Institutions predict that the company's net profit for 2025 may decline by 15.22% year-on-year, reflecting short-term profitability pressure during the expansion phase [3] Group 3: Recent Events - On February 9, 2026, the company announced that Chairman Zhang Yang was relieved from the investigation measures and resumed normal duties, which had been a source of market sentiment pressure since its disclosure in April 2025 [4] - This event is expected to alleviate investor concerns regarding the stability of corporate governance, as evidenced by the stock price stabilizing the day after the announcement and a net inflow of 175 million yuan on February 13, leading to a single-day increase of 4.08% [4] Group 4: Capital Situation - The stock has recently exhibited characteristics of significant capital inflows and outflows, with a cumulative net outflow of over 241 million yuan from February 9 to 12 [5] - However, on February 13, the stock experienced a net inflow of 175 million yuan, with a turnover rate of 11.47%, indicating a low degree of control by major shareholders and an average holding cost of approximately 79-80 yuan [5] - The stock price fluctuation of Sanbo Brain Science is a result of the hype surrounding brain-computer interface concepts, pressure from fundamental expansion, the resolution of actual controller risks, and short-term capital speculation [5]

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]

Group 1 - Jinwei Co., Ltd. plans to acquire 100% equity of Fusheng Mining for 210 million yuan, which will become a wholly-owned subsidiary and included in the consolidated financial statements [2] - Mengguli intends to invest 929 million yuan to build a project with an annual production capacity of 30,000 tons of lithium-ion battery cathode materials, expected to produce 5,000 tons of high-voltage cobalt acid lithium, 10,000 tons of NCA materials, and 15,000 tons of ultra-high nickel ternary materials [2] - Xiamen Tungsten plans to acquire 39% equity of Jiujiang Dadi Mining, which will help increase mineral resource reserves and improve raw material self-sufficiency [3] Group 2 - Andavil's subsidiary received EASA certification for its aviation kitchen plug-in products, marking compliance with European aviation safety standards [2] - CIMC Vehicles disclosed that the US ITC made a preliminary ruling on anti-subsidy and anti-dumping investigations regarding Van-Type Trailers, indicating potential damage to the US domestic industry [4] - Source Technology plans to invest approximately 1.251 billion yuan to build a second phase project for the R&D and production of optoelectronic communication semiconductor chips and devices [9] Group 3 - Zhongmin Energy intends to acquire 51% equity of Mintou Pumped Storage for 864 million yuan, with the transaction price based on asset evaluation [10] - Ningbo Yunsheng plans to publicly issue H-shares and apply for listing on the Hong Kong Stock Exchange [11] - Wenkai Co., Ltd. won a bid for a landscape project worth 50.8162 million yuan [12] Group 4 - China Merchants Shekou achieved a signed sales amount of 7.674 billion yuan in January 2026 [16] - AVIC Optoelectronics reported a net profit of 2.124 billion yuan for 2025, a year-on-year decrease of 36.69% [17] - Tiankang Bio reported a sales revenue of 392 million yuan from pig sales in January 2026, with a month-on-month increase of 6.23% [18] Group 5 - Poly Developments reported a signed amount of 15.617 billion yuan in January 2026, a year-on-year decrease of 13.31% [19] - Chengtou Holdings reported a net profit of 290 million yuan for 2025, a year-on-year increase of 19.67% [20] - Qianjin Pharmaceutical reported a net profit of 288 million yuan for 2025, a year-on-year increase of 24.74% [21]

Core Viewpoint - Sanbo Brain Science (301293) announced the lifting of the investigation measures against its chairman Zhang Yang, allowing him to resume normal duties [1] Group 1 - On February 8, the company received a notice from the Inner Mongolia Autonomous Region Supervisory Committee regarding the lifting of the investigation order [1] - The company confirmed that its operations are currently normal [1] - Zhang Yang, the controlling shareholder and actual controller, is now able to perform his duties as chairman [1]

Core Viewpoint - Sanbo Brain Science (301293) announced the receipt of a notice from the Inner Mongolia Autonomous Region Supervisory Committee on February 8, 2026, indicating the lifting of the order for Mr. Zhang Yang's investigation, allowing him to resume normal duties and operations of the company [1] Group 1 - The company received a "Notice of Lifting the Order for Investigation" from the supervisory committee [1] - The investigation measures against Mr. Zhang Yang have been lifted, allowing him to perform his duties normally [1] - The company is currently operating normally following the resolution of the investigation [1]